Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: A case report

Onkologie(Czech Republic)

Volumn 36, Issue 10, 2013, Pages 578-581

  Loquai, Carmen ^a,c   Müller Brenne, Tina ^a   Schadmand Fischer, Simin ^b   Grabbe, Stephan ^a  

^a Department of Dermatology ^*  (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Biomarker; Immunotherapy; Melanoma; Monoclonal antibody; S100B

Indexed keywords

CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; PROTEIN S100B; VINDESINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CASE REPORT; HUMAN; LUNG METASTASIS; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; MALE; MELANOMA; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84885629771     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355159     Document Type: Article

References (26)

1. Garbe C, Eigentler TK, Keilholz U, et al.: Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24.
2. Eggermont AM, Robert C: New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47:2150-2157.
3. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2011;480:480-489.
4. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
5. Robert C, Thomas L, Bondarenko I, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-2526.
6. Wolchok JD, Hoos A, O'Day S, et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
7. Sharma P, Wagner K, Wolchok JD, et al.: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-812.
8. Hwu P: Treating cancer by targeting the immune system. N Engl J Med 2010;363:779-781.
9. Garbe C, Schadendorf D, Stolz W, et al.: Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008;6(suppl 1):S9-S14.
10. German Cancer Society: S3 Guideline 'Diagnosis, therapy and follow-up care of melanoma'. Short version 1.1., February 2013 [German version]. www.awmf.org/uploads/tx-szleitlinien/032-024k- S3-Melanom-Diagnostik-Therapie- Nachsorge-2013-02.pdf.
11. Palmer SR, Erickson LA, Ichetovkin I, et al.: Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc 2011;86: 981-990.
12. Mocellin S, Zavagno G, Nitti D: The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-Analysis. Int J Cancer 2008;123: 2370-2376.
13. Egberts F, Pollex A, Egberts JH, et al.: Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 2008;31:380-384.
14. Hamberg AP, Korse CM, Bonfrer JM, et al.: Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003;13:45-49.
15. Hauschild A, Engel G, Brenner W, et al.: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-1071.
16. Ghanem G, Loir B, Morandini R, et al.: On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 2001;94:586-590.
17. Acland K, Evans AV, Abraha H, et al.: Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002;146:832-835.
18. Riddle ND, Bui MM: When melanoma is negative for S100: diagnostic pitfalls. Arch Pathol Lab Med 2012;136:237-239.
19. Schiltz PM, Dillman RO, Korse CM, et al.: Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferat- ing tumor cells and dendritic cells. Cancer Biother Radiopharm 2008;23:214-221.
20. Ku GY, Yuan J, Page DB, et al.: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-1775.
21. Kitano S, Postow MA, Cortez C, et al.: Myeloidderived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg to predict for overall survival in patients with metastatic melanoma. J Clin Oncol 2012;30(suppl):abstr 2518.
22. Simone E, Gentilcore G, Romano A, et al.: Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. J Clin Oncol 2012; 30(suppl):abstr 8573.
23. Ellis SG, Wheater M, Tier K, et al.: Biomarker for benefit with ipilimumab: correlation of breadth of humoral tumor-Antigen-specific immunity with outcome. J Clin Oncol 2012;30(suppl):abstr 8566.
24. Reiman JM, Kmieciak M, Manjili MH, et al.: Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007;17:275-287.
25. Hodi FS, Butler M, Oble DA, et al.: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-Associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-3010.
26. ClinicalTrials.gov: A companion study for patients enrolled in prior/parent ipilimumab studies (NCT00162123): a multi-center, open-label, phase II study of ipilimumab (MDX-010) extended-treatment monotherapy or follow-up for patients previously enrolled in ipilimumab (MDX-010) protocols. http://clinicaltrials.gov/show/NCT00162123.